1. Home
  2. GTY vs KOD Comparison

GTY vs KOD Comparison

Compare GTY & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GTY

Getty Realty Corporation

HOLD

Current Price

$36.09

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$42.25

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTY
KOD
Founded
1955
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
1998
2018

Fundamental Metrics

Financial Performance
Metric
GTY
KOD
Price
$36.09
$42.25
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$32.60
$35.43
AVG Volume (30 Days)
533.0K
858.4K
Earning Date
04-22-2026
05-14-2026
Dividend Yield
5.92%
N/A
EPS Growth
8.00
N/A
EPS
0.43
N/A
Revenue
$221,727,000.00
N/A
Revenue This Year
$9.39
N/A
Revenue Next Year
$7.83
N/A
P/E Ratio
$83.93
N/A
Revenue Growth
9.02
N/A
52 Week Low
$25.39
$5.00
52 Week High
$36.12
$47.84

Technical Indicators

Market Signals
Indicator
GTY
KOD
Relative Strength Index (RSI) 73.33 61.43
Support Level $32.41 $39.37
Resistance Level N/A $46.72
Average True Range (ATR) 0.58 3.18
MACD 0.18 0.45
Stochastic Oscillator 87.54 81.37

Price Performance

Historical Comparison
GTY
KOD

About GTY Getty Realty Corporation

Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: